SANOFI

Drug pipeline (237)

Asset	Stage	Revenue	Trials	Status
ACCURBRON	approved	—	1	approved
ACTHAR	approved	—	0	—
ACTHIB,OMNIHIB	approved	—	0	—
ADACEL	approved	—	0	—
ADLYXIN	approved	—	36	approved

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (2109)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT00046150	phase3	completed	2002-05-01	—	Sanofi	12 Week,Comparing Safety of HMR1964 & Insulin Aspart Used in Continuous Subcutaneous Infusion in Type 1 Diabetes.
NCT00103649	phase3	completed	2003-11-01	2007-10-01	Sanofi	18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type
NCT00563225	phase3	completed	2002-10-01	—	Sanofi	20 Week Bridging Study in Type II DM
NCT00976937	phase3	completed	2009-08-01	2011-03-01	Sanofi	24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
NCT00975286	phase3	completed	2009-10-01	2011-08-01	Sanofi	24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine

FDA applications (193)

Application

Approved

Type

Applicant

Products

BLA 761445

2026-07-09

BLA

SANOFI-AVENTIS U.S. LLC

BLA 125817

2025-05-16

BLA

SANOFI VACCINES US INC.

BLA 761325

2025-02-14

BLA

SANOFI-AVENTIS U.S. LLC

BLA 761328

2023-07-17

BLA

SANOFI VACCINES US INC.

BLA 125771

2023-02-22

BLA

BIOVERATIV THERAPEUTICS, INC.